Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin with Cisplatin and Radiation in HNSCC
NCT02325401Phase 1Completed
- Sponsor
- University of Cincinnati
- Start
- May 2015
- Primary completion
- Dec 2017
- Countries
- 1
01
Overview
Phase 1, open-label trial of metformin in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Cincinnati. Primary endpoint: Maximum Tolerated Dose of Metformin at 24 months. Started May 2015; status: completed.
02
Drugs
metformin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02325401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02325401.